Nav: Home

Mathematics for child health

December 21, 2015

Many people in Russia know about the Dima Rogachev Centre - particularly those who have faced the challenge of child cancer. The centre is Europe's largest pediatric cancer care facility and is named after a boy with advanced cancer who wrote a letter to President Putin inviting him to visit; the invitation was accepted, and after the visit, the decision was made to build a state-of-the-art Centre for Pediatric Hematology, Oncology and Immunology, based in the Research Institute of Pediatric Hematology. The new centre was named after Dmitry 'Dima' Rogachev who died two years later at the age of 12 while the centre was still under construction.

Doctors Seeking Help from Mathematicians


There is a waiting list for the centre which provides the best pediatric cancer treatment available in Russia - for example, lymphoblastic leukemia used to be a largely fatal condition in Russia in the early 1990s, and its ten-year survival rates did not exceed 10%. Today, the survival rate is 85%, yet further progress beyond this has been a struggle.

In 2011, Russian oncologists looked beyond what medicine could offer, and Alexander Karachunsky, Deputy Director for Research of the Federal Research Center of Pediatric Hematology, Oncology, and Immunology (the Dmitry Rogachev Centre) contacted the HSE School of Data Analysis and Artificial Intelligence. "He hoped that the mathematicians and programmers there could help doctors with data analysis and the modeling of disease progression and treatment response," according to Sergei Kuznetsov, Head of the School, "and he asked us to find out why certain drugs and therapies work for some patients, but not others. The medics were interested in how the treatment response might vary depending on the patient's physiology, such as the state of the internal organs and blood, and the role of genetics."

A Personalised Approach


Many doctors now believe that it may be possible to identify patient subgroups for whom the use of a particular drug or type of therapy can be preferable, based on patient profiles.

Today, personalised medicine is an important trend in health care and particularly in pharmacology. It means that the choice of drugs and treatment regimens is based on the patient's individual profile, including their physiological, biochemical and genetic makeup, and other parameters. Rather than treat the disease, medics are moving towards treating a specific person. In fact, the traditional approach where drugs are designed and administered to treat a certain ailment has been found ineffective in many cases. According to the WHO, conventional pharmacology fails to produce the desired effect in 20% to 70% of ulcer patients, 5% to 57% of diabetes patients, 10% to 75% of hypertension patients, and 70% to 100% of cancer patients. Many experts argue that taking into account individual characteristics, including genetic factors, may be particularly important in cancer treatment.

Genome sequencing and the use of mathematical methods for clinical data processing can support the advancement of personalised medicine. Thus, a team of HSE mathematicians were asked to systematise and analyse patients' personal data to inform better treatment choices.

The Scientific Method


The researchers set out to develop a methodology for identifying patient subgroups with significant differences in terms of response to certain treatments, specifically two types of chemotherapy, DEXA and MEDROL. The study compared patients with similar physiological profiles receiving different types of treatment.

The study was based on data from 1,773 patients aged 18 and younger diagnosed with acute lymphoblastic leukemia. The calculation takes into account the patient' gender, age at diagnosis, status of internal organs (liver, spleen, central nervous system), immunophenotype - i.e. cell characteristics obtained using monochannel antibodies - and other factors. "The interaction of certain factors may be more complex than we can currently imagine, including thousands and even millions of possible combinations," according to researcher Natalia Korepanova of the School of Data Analysis and Artificial Intelligence. She also explains that mathematical modeling helps to identify any links between different combinations of these characteristics and their correlation with the treatment effect.

Trees and Lattices


First, the researchers used machine learning methods, namely decision trees, for data analysis. This model uses several input variables (i.e. the tree roots) to determine potential values of the target variable (i.e. the tree leaves). While decision trees enable relatively fast processing of very large data sets, according to Kuznetsov, this method has a downside, i.e. a degree of randomness in the selection of competing options (branches). "If we select the wrong branch to begin with, we can no longer go back to the right option. But when the stakes are high, we can use global optimisation, which can take time, but produces a comprehensive picture." Therefore, as their next step, they applied a formal concept analysis to review all possible options and visualise object-attribute correlations using formal concept lattices, a.k.a. Galois lattices. This approach makes it possible to construct a lattice based on any binary relation or a mathematical description of a concept as an object-attribute pair.

The above analysis has identified distinct patient groups which respond differently to the same treatment. The following is an example of a hypothesis confirmed with 95% reliability and 85% sensitivity: MEDROL is more effective than DEXA in patients aged 6.6, with the spleen size of at least 3.5 and pre-pre-B or pre-B immunophenotype, a total of 47 patients in the sample. If all patients are treated with MEDROL, eight would be saved.

The researchers came up with a procedure for identifying patient subgroups responding differently to two types of treatment. "Identifying smaller groups with significant differences between them is fairly easy," notes Kuznetsov, "but only clinical trials can fully confirm the hypotheses." Conducting such clinical trials is the key objective of the Centre's medics today. In addition to this, the researchers are now addressing a few remaining questions, e.g. how to modify the process for comparing three or more different treatment strategies, how to take into account adverse events such as recurrence and metastasis, and others. According to Kuznetsov, the procedure they have developed can be easily adapted to any subgroup analysis, and is not limited to hematology and medicine.

Now it is up to medics to interpret the study's results and come up with a clinical decision. Dozens of patients, without knowing it, are waiting for a confirmation that the method works. These patients may never know who they should credit for the solution, but the medics of the Dima Rogachev Centre are now certain that the can always turn to HSE mathematicians for assistance.
-end-


National Research University Higher School of Economics

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
Review examines diversity in dermatology clinical trials
Racial and ethnic groups can be underrepresented in medical research.
Reshaping the future of global clinical trials practice
Researchers at the University of Liverpool have developed a new international guideline to help standardize how results from clinical trial studies are reported.
Fewer cardiovascular drugs being studied in clinical trials
The number of cardiovascular drugs in the research pipeline has declined across all phases of development in the last 20 years even as cardiovascular disease has become the No.
Sex hormones skew outcomes in clinical trials -- here's how
Clinical research often excludes females from their trials under the assumption that 'one size fits all,' that a painkiller or antidepressant will be equally effective in subjects of either sex, but a growing number of scientists are criticizing this approach.
Nearly half of pediatric clinical trials go unfinished or unpublished
Clinical trials in children commonly go either uncompleted or unpublished, finds a comprehensive study conducted by researchers at Boston Children's Hospital.

Related Clinical Trials Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.